Compare NRG Energy Inc (NRG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Viatris Inc — how do they compare? NRG Energy Inc trades at $107.97 (market cap $22.35B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: NRG Energy Inc and Viatris Inc are close in size by market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold NRG Energy Inc for 63 Days and Viatris Inc for 57 Days on average.
| NRG | VTRS | |
|---|---|---|
Market Cap | $22.35B | $20.03B |
Volume | 5,011,942 | 14,109,977 |
Sector | Utilities | Health |
52-Week High | $184.03 | $18.27 |
52-Week Low | $95.23 | $9.74 |
Typical Hold Time | 63 Days | 57 Days |
Enterprise Value | $46.30B | $32.15B |
Dividend Yield | 1.79% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $106.32, down 2.11% today, with a bullish technical signal and strong analyst support. The stock shows mixed earnings performance with recent misses but maintains solid fundamentals including $30.71B revenue and 2.56% net margin. Recent developments include a 1.2 GW Texas data center power project and potential acquisition of a West Virginia coal plant, positioning for growth in energy infrastructure.
Outlook remains positive with 70% analyst buy ratings and $202.90 consensus price target representing 91% upside. Key risks include execution of major capital projects, debt levels at 56.42% of assets, and energy market volatility. The dividend yield of approximately 1.6% provides income support while growth initiatives drive long-term potential.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
